AR032626A1 - Amidas, composiciones farmaceuticas que las comprenden, proceso para preparar dichas composiciones, uso de dichas amidas en la preparacion de medicamentos, y proceso para la preparacion de dichas amidas - Google Patents
Amidas, composiciones farmaceuticas que las comprenden, proceso para preparar dichas composiciones, uso de dichas amidas en la preparacion de medicamentos, y proceso para la preparacion de dichas amidasInfo
- Publication number
- AR032626A1 AR032626A1 ARP010103437A ARP010103437A AR032626A1 AR 032626 A1 AR032626 A1 AR 032626A1 AR P010103437 A ARP010103437 A AR P010103437A AR P010103437 A ARP010103437 A AR P010103437A AR 032626 A1 AR032626 A1 AR 032626A1
- Authority
- AR
- Argentina
- Prior art keywords
- lower alkyl
- atom
- preparation
- amidas
- ring
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 6
- 125000004432 carbon atom Chemical group C* 0.000 abstract 5
- 150000001408 amides Chemical class 0.000 abstract 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 3
- 125000001475 halogen functional group Chemical group 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 239000001301 oxygen Substances 0.000 abstract 3
- 229910052717 sulfur Chemical group 0.000 abstract 3
- 239000011593 sulfur Chemical group 0.000 abstract 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 2
- 125000004414 alkyl thio group Chemical group 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 150000002431 hydrogen Chemical class 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- 101100516554 Caenorhabditis elegans nhr-5 gene Proteins 0.000 abstract 1
- 102000030595 Glucokinase Human genes 0.000 abstract 1
- 108010021582 Glucokinase Proteins 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000003368 amide group Chemical group 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 229910052757 nitrogen Chemical group 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/46—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylureas
- C07C275/48—Y being a hydrogen or a carbon atom
- C07C275/50—Y being a hydrogen or an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
- C07C317/46—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/18—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
- C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Pyrane Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21987200P | 2000-07-20 | 2000-07-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR032626A1 true AR032626A1 (es) | 2003-11-19 |
Family
ID=22821104
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010103437A AR032626A1 (es) | 2000-07-20 | 2001-07-18 | Amidas, composiciones farmaceuticas que las comprenden, proceso para preparar dichas composiciones, uso de dichas amidas en la preparacion de medicamentos, y proceso para la preparacion de dichas amidas |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US6486184B2 (enExample) |
| EP (1) | EP1305301B1 (enExample) |
| JP (1) | JP4138478B2 (enExample) |
| KR (1) | KR100556323B1 (enExample) |
| CN (1) | CN1184214C (enExample) |
| AR (1) | AR032626A1 (enExample) |
| AT (1) | ATE297907T1 (enExample) |
| AU (2) | AU2001287600B2 (enExample) |
| BR (1) | BR0112658A (enExample) |
| CA (1) | CA2416229C (enExample) |
| DE (1) | DE60111534T2 (enExample) |
| DK (1) | DK1305301T3 (enExample) |
| ES (1) | ES2243547T3 (enExample) |
| GT (1) | GT200100146A (enExample) |
| MX (1) | MXPA03000365A (enExample) |
| PA (1) | PA8522701A1 (enExample) |
| PE (1) | PE20020335A1 (enExample) |
| PT (1) | PT1305301E (enExample) |
| UY (1) | UY26850A1 (enExample) |
| WO (1) | WO2002008209A1 (enExample) |
| ZA (1) | ZA200300173B (enExample) |
Families Citing this family (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0102299D0 (sv) | 2001-06-26 | 2001-06-26 | Astrazeneca Ab | Compounds |
| SE0102764D0 (sv) | 2001-08-17 | 2001-08-17 | Astrazeneca Ab | Compounds |
| EP1336607A1 (en) * | 2002-02-19 | 2003-08-20 | Novo Nordisk A/S | Amide derivatives as glucokinase activators |
| WO2003055482A1 (en) * | 2001-12-21 | 2003-07-10 | Novo Nordisk A/S | Amide derivatives as gk activators |
| DE60309856T2 (de) | 2002-04-26 | 2007-06-14 | F. Hoffmann-La Roche Ag | Substituierte phenylacetamide und deren verwendung als glucokinaseaktivatoren |
| KR101124245B1 (ko) | 2002-06-27 | 2012-07-02 | 노보 노르디스크 에이/에스 | 치료제로서 아릴 카르보닐 유도체 |
| AU2003243921B2 (en) | 2002-06-27 | 2009-05-07 | Novo Nordisk A/S | Aryl carbonyl derivatives as therapeutic agents |
| MXPA05003559A (es) | 2002-10-03 | 2005-06-03 | Novartis Ag | (tiazol-2-il)-amida o sulfonamida substituida como activadores de glicocinasa utiles en el tratamiento de diabetes de tipo 2. |
| GB0226931D0 (en) | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
| MY141521A (en) | 2002-12-12 | 2010-05-14 | Hoffmann La Roche | 5-substituted-six-membered heteroaromatic glucokinase activators |
| WO2004063194A1 (en) * | 2003-01-06 | 2004-07-29 | Eli Lilly And Company | Heteroaryl compounds |
| PL378117A1 (pl) * | 2003-02-11 | 2006-03-06 | Prosidion Limited | Tricyklopodstawione związki amidowe |
| MXPA06003474A (es) | 2003-09-30 | 2006-06-05 | Novo Nordisk As | Agonistas de receptores de melanocortina. |
| WO2005056036A2 (en) | 2003-12-09 | 2005-06-23 | Novo Nordisk A/S | Regulation of food preference using glp-1 agonists |
| PT1723128E (pt) | 2004-01-06 | 2013-02-27 | Novo Nordisk As | Heteroaril-ureias e o seu uso como activadores da glicoquinase |
| AU2005229416B2 (en) | 2004-04-02 | 2009-03-26 | Novartis Ag | Sulfonamide-thiazolpyridine derivatives as glucokinase activators useful the treatment of type 2 diabetes |
| KR20070006816A (ko) | 2004-04-02 | 2007-01-11 | 노파르티스 아게 | 티아졸로피리딘 유도체, 이를 함유하는 제약 조성물 및글루코키나제 매개형 증상의 치료 방법 |
| EA012204B1 (ru) * | 2004-04-21 | 2009-08-28 | Прозидион Лимитед | Три(цикло)замещённые амидные соединения |
| UA90264C2 (ru) * | 2004-04-21 | 2010-04-26 | Прозидион Лтд. | Три(цикло)замещенные амиды, фармацевтическая композиция, способы лечения и профилактики, способ получения соединения |
| EP1758575A1 (en) | 2004-06-11 | 2007-03-07 | Novo Nordisk A/S | Counteracting drug-induced obesity using glp-1 agonists |
| AU2005271016A1 (en) * | 2004-08-12 | 2006-02-16 | Prosidion Limited | Substituted phenylacetamides and their use as glucokinase activators |
| GB0418046D0 (en) * | 2004-08-12 | 2004-09-15 | Prosidion Ltd | Eantioselective process |
| KR20080024211A (ko) * | 2005-07-08 | 2008-03-17 | 노보 노르디스크 에이/에스 | 디시클로알킬 우레아 글루코키나제 활성제 |
| JP2009500378A (ja) | 2005-07-08 | 2009-01-08 | ノボ・ノルデイスク・エー／エス | グルコキナーゼ活性化剤としてのジシクロアルキルカルバモイル尿素 |
| NZ564608A (en) | 2005-07-09 | 2009-09-25 | Astrazeneca Ab | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes |
| BRPI0612996A2 (pt) * | 2005-07-14 | 2010-12-14 | Novo Nordisk As | ativadores de urÉia glucocinase |
| US8106090B2 (en) | 2005-07-20 | 2012-01-31 | Eli Lilly And Company | 1-amino linked compounds |
| EP1921074A1 (en) | 2005-08-31 | 2008-05-14 | Astellas Pharma Inc. | Thiazole derivative |
| JP2007063225A (ja) | 2005-09-01 | 2007-03-15 | Takeda Chem Ind Ltd | イミダゾピリジン化合物 |
| CA2624102A1 (en) | 2005-09-29 | 2007-04-12 | Sanofi-Aventis | Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals |
| GT200600428A (es) | 2005-09-30 | 2007-05-21 | Compuestos organicos | |
| GT200600429A (es) | 2005-09-30 | 2007-04-30 | Compuestos organicos | |
| JP2009514835A (ja) * | 2005-11-03 | 2009-04-09 | プロシディオン・リミテッド | トリシクロ置換型アミド |
| DK1951658T3 (da) | 2005-11-17 | 2012-10-15 | Lilly Co Eli | Glucagonreceptorantagonister, fremstilling og terapeutiske anvendelser |
| US20070197532A1 (en) * | 2005-11-18 | 2007-08-23 | Cao Sheldon X | Glucokinase activators |
| US8034822B2 (en) | 2006-03-08 | 2011-10-11 | Takeda San Diego, Inc. | Glucokinase activators |
| PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
| JP5386350B2 (ja) | 2006-05-31 | 2014-01-15 | タケダ カリフォルニア インコーポレイテッド | グルコキナーゼ活性剤としての、インダゾールおよびイソインドール誘導体 |
| US7910747B2 (en) | 2006-07-06 | 2011-03-22 | Bristol-Myers Squibb Company | Phosphonate and phosphinate pyrazolylamide glucokinase activators |
| US7888504B2 (en) | 2006-07-06 | 2011-02-15 | Bristol-Myers Squibb Company | Glucokinase activators and methods of using same |
| US8022066B2 (en) | 2006-11-15 | 2011-09-20 | High Point Pharmaceuticals, Llc | 2-(2-hydroxyphenyl) benzothiadiazines useful for treating obesity and diabetes |
| US7902248B2 (en) | 2006-12-14 | 2011-03-08 | Hoffmann-La Roche Inc. | Oxime glucokinase activators |
| JP5419706B2 (ja) | 2006-12-20 | 2014-02-19 | タケダ カリフォルニア インコーポレイテッド | グルコキナーゼアクチベーター |
| TW200831081A (en) * | 2006-12-25 | 2008-08-01 | Kyorin Seiyaku Kk | Glucokinase activator |
| US8138185B2 (en) | 2007-01-09 | 2012-03-20 | Novo Nordisk A/S | Urea glucokinase activators |
| AU2008204530B2 (en) | 2007-01-11 | 2013-08-01 | Vtv Therapeutics Llc | Urea glucokinase activators |
| CN101622231B (zh) * | 2007-02-28 | 2013-12-04 | 艾德维纳斯医疗私人有限公司 | 作为葡糖激酶激活剂的2，2，2-三取代的乙酰胺衍生物、它们的制造方法和药学应用 |
| MX2009009525A (es) * | 2007-03-07 | 2009-09-16 | Kyorin Seiyaku Kk | Activador de glucocinasa. |
| WO2008116107A2 (en) * | 2007-03-21 | 2008-09-25 | Takeda San Diego, Inc. | Piperazine derivatives as glucokinase activators |
| ES2446932T3 (es) | 2007-10-08 | 2014-03-10 | Advinus Therapeutics Private Limited | Derivados de acetamida como activadores de glucoquinasa, su procedimiento y aplicaciones en medicina |
| US9340506B2 (en) | 2007-10-08 | 2016-05-17 | Advinus Therapeutics Limited | Acetamide derivatives as glucokinase activators, their process and medicinal applications |
| TW200934772A (en) * | 2008-01-15 | 2009-08-16 | Lilly Co Eli | Crystalline(R)-2-(4-cyclopropanesulphonyl-phenyl)-N-pyrazin-2-yl-3-(tetrahydropyran-4-yl)-propionamide |
| EP2236498A4 (en) | 2008-01-18 | 2012-02-22 | Astellas Pharma Inc | PHENYLACETAMIDE DERIVATIVE |
| HRP20150842T1 (hr) | 2008-04-28 | 2015-09-11 | Kyorin Pharmaceutical Co., Ltd. | Derivati ciklopentilakrilamida |
| EA018988B1 (ru) | 2008-05-16 | 2013-12-30 | Такеда Калифорния, Инк. | Активаторы глюкокиназы |
| WO2010150280A1 (en) | 2009-06-22 | 2010-12-29 | Cadila Healthcare Limited | Disubstituted benzamide derivatives as glucokinase (gk) activators |
| MY156175A (en) | 2009-07-31 | 2016-01-15 | Cadila Healthcare Ltd | Substituted benzamide derivatives as glucokinase (gk) activators |
| WO2011080755A1 (en) | 2009-12-29 | 2011-07-07 | Advinus Therapeutics Private Limited | Fused nitrogen heterocyclic compounds, process of preparation and uses thereof |
| WO2011095997A1 (en) | 2010-02-08 | 2011-08-11 | Advinus Therapeutics Private Limited | Benzamide compounds as glucokinase activators and their pharmaceutical application |
| BR112012021231A2 (pt) | 2010-02-26 | 2015-09-08 | Basf Plant Science Co Gmbh | método para acentuar o rendimento em plantas, planta, construto, uso de um construto, método para a produção de uma planta transgênica, partes coletáveis de uma planta, produtos derivados de uma planta, uso de um ácido nucleíco e método para a produção de um produto |
| WO2011104378A1 (en) | 2010-02-26 | 2011-09-01 | Novo Nordisk A/S | Peptides for treatment of obesity |
| EP2552950A1 (en) | 2010-03-26 | 2013-02-06 | Novo Nordisk A/S | Novel glucagon analogues |
| EP2553086B1 (en) | 2010-03-31 | 2017-04-19 | The Scripps Research Institute | Reprogramming cells |
| EP2402327B1 (en) | 2010-06-29 | 2018-03-07 | Impetis Biosciences Ltd. | Acetamide compounds as glucokinase activators, their process and medicinal applications |
| RU2013145013A (ru) | 2011-03-28 | 2015-05-10 | Ново Нордиск А/С | Новые аналоги глюкагона |
| MY167234A (en) | 2011-09-23 | 2018-08-14 | Novo Nordisk As | Novel glucagon analogues |
| MY174727A (en) | 2013-04-18 | 2020-05-11 | Novo Nordisk As | Stable, protracted glp-1/glucagon receptor co-agonists for medical use |
| US10570184B2 (en) | 2014-06-04 | 2020-02-25 | Novo Nordisk A/S | GLP-1/glucagon receptor co-agonists for medical use |
| JP2020514365A (ja) | 2017-03-15 | 2020-05-21 | ノヴォ ノルディスク アー／エス | メラノコルチン４受容体に結合可能な二環式化合物 |
| WO2019219714A1 (en) | 2018-05-15 | 2019-11-21 | Novo Nordisk A/S | Compounds capable of binding to melanocortin 4 receptor |
| AU2019287437A1 (en) | 2018-06-12 | 2020-09-10 | Vtv Therapeutics Llc | Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs |
| WO2020053414A1 (en) | 2018-09-14 | 2020-03-19 | Novo Nordisk A/S | Bicyclic compounds capable of acting as melanocortin 4 receptor agonists |
| WO2021167840A1 (en) | 2020-02-18 | 2021-08-26 | Vtv Therapeutics Llc | Sulfoxide and sulfone glucokinase activators and methods of use thereof |
| CN116194442A (zh) | 2020-06-08 | 2023-05-30 | 维特卫治疗有限责任公司 | {2-[3-环己基-3-(反式-4-丙氧基-环己基)-脲基]-噻唑-5-基硫烷基}-乙酸的盐或共晶体及其用途 |
| CN117209448A (zh) * | 2023-09-13 | 2023-12-12 | 济宁医学院 | 含(苯并)噻唑硫代/硒代乙酰胺及其衍生物的制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3776917A (en) * | 1972-06-05 | 1973-12-04 | Schering Corp | 2-amino-6-phenalkyl-aminopyridines and derivatives thereof |
| JPS5564592A (en) * | 1978-11-10 | 1980-05-15 | Teijin Ltd | Thiazolo 3, 2-a pyrimidine derivative, its preparation, and drug comprising it |
| JPS62153273A (ja) * | 1985-12-26 | 1987-07-08 | Tokuyama Soda Co Ltd | ピラゾ−ル化合物 |
| CZ301366B6 (cs) * | 1999-03-29 | 2010-02-03 | F. Hoffmann-La Roche Ag | 2-Fenyl-3-cykloalkylpropionamidová sloucenina, zpusob její prípravy a farmaceutický prostredek s jejím obsahem |
-
2001
- 2001-07-11 PT PT01967150T patent/PT1305301E/pt unknown
- 2001-07-11 DK DK01967150T patent/DK1305301T3/da active
- 2001-07-11 MX MXPA03000365A patent/MXPA03000365A/es active IP Right Grant
- 2001-07-11 AT AT01967150T patent/ATE297907T1/de not_active IP Right Cessation
- 2001-07-11 DE DE60111534T patent/DE60111534T2/de not_active Expired - Lifetime
- 2001-07-11 KR KR1020037000822A patent/KR100556323B1/ko not_active Expired - Fee Related
- 2001-07-11 AU AU2001287600A patent/AU2001287600B2/en not_active Ceased
- 2001-07-11 CN CNB01813050XA patent/CN1184214C/zh not_active Expired - Fee Related
- 2001-07-11 CA CA002416229A patent/CA2416229C/en not_active Expired - Fee Related
- 2001-07-11 JP JP2002514115A patent/JP4138478B2/ja not_active Expired - Fee Related
- 2001-07-11 WO PCT/EP2001/007994 patent/WO2002008209A1/en not_active Ceased
- 2001-07-11 AU AU8760001A patent/AU8760001A/xx active Pending
- 2001-07-11 EP EP01967150A patent/EP1305301B1/en not_active Expired - Lifetime
- 2001-07-11 BR BR0112658-0A patent/BR0112658A/pt not_active IP Right Cessation
- 2001-07-11 ES ES01967150T patent/ES2243547T3/es not_active Expired - Lifetime
- 2001-07-13 US US09/905,152 patent/US6486184B2/en not_active Expired - Fee Related
- 2001-07-18 PA PA20018522701A patent/PA8522701A1/es unknown
- 2001-07-18 AR ARP010103437A patent/AR032626A1/es active IP Right Grant
- 2001-07-19 PE PE2001000731A patent/PE20020335A1/es not_active Application Discontinuation
- 2001-07-19 UY UY26850A patent/UY26850A1/es not_active Application Discontinuation
- 2001-07-20 GT GT200100146A patent/GT200100146A/es unknown
-
2002
- 2002-06-25 US US10/179,717 patent/US6608218B2/en not_active Expired - Fee Related
-
2003
- 2003-01-07 ZA ZA200300173A patent/ZA200300173B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK1305301T3 (da) | 2005-10-17 |
| GT200100146A (es) | 2002-07-04 |
| PT1305301E (pt) | 2005-09-30 |
| PE20020335A1 (es) | 2002-04-30 |
| JP4138478B2 (ja) | 2008-08-27 |
| ES2243547T3 (es) | 2005-12-01 |
| US20020042512A1 (en) | 2002-04-11 |
| BR0112658A (pt) | 2003-06-24 |
| EP1305301A1 (en) | 2003-05-02 |
| CN1443177A (zh) | 2003-09-17 |
| US20020198200A1 (en) | 2002-12-26 |
| CA2416229C (en) | 2007-09-18 |
| JP2004504388A (ja) | 2004-02-12 |
| CA2416229A1 (en) | 2002-01-31 |
| PA8522701A1 (es) | 2002-10-24 |
| KR20030016419A (ko) | 2003-02-26 |
| DE60111534T2 (de) | 2006-05-11 |
| KR100556323B1 (ko) | 2006-03-03 |
| EP1305301B1 (en) | 2005-06-15 |
| AU2001287600B2 (en) | 2006-07-13 |
| WO2002008209A1 (en) | 2002-01-31 |
| MXPA03000365A (es) | 2003-05-27 |
| CN1184214C (zh) | 2005-01-12 |
| US6486184B2 (en) | 2002-11-26 |
| US6608218B2 (en) | 2003-08-19 |
| DE60111534D1 (de) | 2005-07-21 |
| ZA200300173B (en) | 2004-04-07 |
| ATE297907T1 (de) | 2005-07-15 |
| UY26850A1 (es) | 2002-01-31 |
| AU8760001A (en) | 2002-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR031066A1 (es) | Un compuesto que comprende una amida, un proceso para su preparacion, composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos | |
| AR032453A1 (es) | Derivados alquinil fenil heteroaromaticos activadores de glucoquinasa, un proceso para su preparacion, composiciones farmaceuticas, el uso de dichos derivados para la preparacion de medicamentos | |
| AR018634A1 (es) | Derivados de benzo(b)tiepin-1,1,-dioxido, procedimiento para su preparacion, medicamentos conteniendo estos compuestos, procedimiento para la preparacion de medicamentos y su empleo para la preparacion de medicamentos. | |
| AR065937A2 (es) | Compuesto derivado indazol, composicion farmaceutica que lo comprende y su uso en la fabricacion de medicamentos para modular la actividad de proteina quinasa | |
| AR030279A1 (es) | Derivados de fenilamida para-amino sustituida activadora de la glucoquinasa, un procedimiento para su preparacion, composiciones farmaceuticas y el empleo de dichos derivados para la preparacion de medicamentos. | |
| AR032752A1 (es) | Ureido propionamidas o propionamidas heteroaromaticas trans olefinicas 2,3-di-sustituidas, un proceso para su preparacion, composiciones farmaceuticas que los comprenden y el uso de las mismas para la manufactura de un medicamento como activadores de glucoquinasa | |
| AR038000A1 (es) | Compuesto derivado de tien[2,3-d]pirimidin-2,4(1h,3h)-diona, composicion farmaceutica, proceso para su preparacion y su uso en la fabricacion de un medicamento | |
| CO5251381A1 (es) | Derivados de adamantano, un proceso para su preparacion y composiciones farmaceuticas que los contienen | |
| AR034268A1 (es) | Compuestos derivados de piperidina, su uso en preparacion de medicamentos, composicion farmaceutica, metodo de tratamiento y proceso para su preparacion | |
| CO5550421A2 (es) | Derivados de indol utiles para el tratamiento de enfermeda- des | |
| UY28132A1 (es) | Derivados de pirrolopirimidina | |
| AR035639A1 (es) | Derivados de para-aril o heterociclil sustituidos activadores de fenilglucoquinasa, un proceso para su preparacion, composicion farmaceutica y el uso de dichos derivados para la preparacion de medicamentos. | |
| AR046244A1 (es) | Activadores de glucoquinasa heteroaromaticos de seis miembros 5- sustituidos | |
| AR036659A1 (es) | Compuestos derivados de fenil-piperazina, fenil-piperidina y fenil-tetrahidropiridina como inhibidores de la reabsorcion de la serotonina, una composicion farmaceutica y utilizacion de los mismos para la preparacion de medicamentos | |
| AR035516A1 (es) | Sulfonamidas heterociclicas y el uso de las mismas para la preparacion de medicamentos que inhiben la produccion de amiloides beta | |
| AR033525A1 (es) | Arilmetilaminas sustituidas, composiciones farmaceuticas, uso de las mismas para la manufactura de un medicamento | |
| AR041009A1 (es) | Compuestos heterociclicos nitrogenados que presentan actividad inhibitoria contra la integrasa del vih | |
| AR032621A1 (es) | Compuestos derivados de tiofeno, metodo para su preparacion, composicion farmaceutica y uso en la fabricacion de medicamentos | |
| AR019789A2 (es) | Compuestos derivados de la eritromicina, composiciones que los contienen, uso de los mismos para preparar un medicamento | |
| AR036672A1 (es) | Derivados de pirrolidinona | |
| AR088808A2 (es) | Derivados de 2h-piridazin-3-ona, composiciones farmaceuticas que los contienen y un proceso para la preparacion de dichos derivados y el uso de dichos derivados para la preparacion de una composicion farmaceutica | |
| BR0112658A (pt) | Ativadores de benzeno-acetamida-glucoquinase substituìdos por alfa-acil e alfa heteroátomos | |
| AR058073A1 (es) | Derivados de imidazol 5-il-pirimidina, procesos de obtencion, composiciones farmaceuticas y usos | |
| AR017177A1 (es) | Compuesto derivados de 9-amino-3-ceto eritromicina, composiciones farmaceuticas, uso para la preparacion de un medicamento y procedimientos de preparacion. | |
| UY29312A1 (es) | Piperazin-1-carboxamidas n,4,sustituidas y sus derivados, composiciones que los contienen, procedimientos de preparación y aplicaciones |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |